Will the gene-editing blood-fat treatment report no treatment-related serious events at November’s AHA meeting?

Question

This market will resolve YES if the November 9 AHA 2026 presentation of CTX310 Phase 1b in severe hypertriglyceridemia explicitly reports zero serious adverse events attributed to CTX310 in the disclosed Phase 1b safety population. CTX310 uses gene editing to target ANGPTL3 and lower blood fats. This is a safety-data question about the new Phase 1b readout, not the already published Phase 1a results from 2025 or August 2026.

The investigators' classification of serious and treatment-related con

Problyx · Accepted Answer

Yes — the community forecast puts this at 75%.

Problyx · Answer

No — the community forecast puts this at 25%.